RegenBio Summit: Understanding regulations for bringing breakthrough treatments to patients

Learn about navigating regulatory pathways that advance promising biotherapies to daily patient care at RegenBio Summit: Transforming Next-Gen Biotherapeutics 2024.  Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research within the Food and Drug Administration (FDA), will deliver a keynote address about guiding the development of new cell, gene and tissue therapies. Dr. Marks leads the Center within FDA that is responsible for ensuring that biological products are safe, effective and…

Source: View source